Gossamer Bio (NASDAQ:GOSS) Given New $32.00 Price Target at Wedbush

Gossamer Bio (NASDAQ:GOSS) had its price objective decreased by Wedbush to $32.00 in a research report released on Wednesday morning, MarketBeat reports. Wedbush currently has a neutral rating on the stock.

GOSS has been the subject of several other research reports. Weiss Ratings downgraded shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. Leerink Partners upgraded Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective on the stock in a research note on Tuesday, July 28th. HC Wainwright reiterated a “buy” rating on shares of Gossamer Bio in a report on Thursday, August 27th. Chardan Capital reiterated a “buy” rating on shares of Gossamer Bio in a report on Monday, October 26th. Finally, Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $246.40.

Gossamer Bio Stock Performance

Shares of GOSS stock opened at $11.69 on Wednesday. Gossamer Bio has a fifty-two week low of $8.29 and a fifty-two week high of $309.60. The company has a 50 day moving average price of $10.67 and a 200 day moving average price of $34.94.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Tuesday, November 10th. The company reported ($7.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.79) by ($3.57). The business had revenue of $38.43 million for the quarter, compared to the consensus estimate of $12.16 million. On average, equities analysts predict that Gossamer Bio will post -33.00 earnings per share for the current year.

Institutional Trading of Gossamer Bio

Several hedge funds have recently added to or reduced their stakes in the company. Hsbc Holdings PLC acquired a new position in Gossamer Bio during the 1st quarter worth approximately $38,000. SG Americas Securities LLC increased its position in shares of Gossamer Bio by 73.4% in the 1st quarter. SG Americas Securities LLC now owns 128,568 shares of the company’s stock valued at $42,000 after purchasing an additional 54,439 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of Gossamer Bio in the 2nd quarter valued at $35,000. Bank of America Corp DE acquired a new stake in shares of Gossamer Bio in the 2nd quarter valued at $65,000. Finally, Ieq Capital LLC acquired a new stake in shares of Gossamer Bio in the 2nd quarter valued at $97,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders. Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.